Breast Cancer Core Needle Biopsy Market Size, Share & Trends Analysis Report By Technology, By End-Use (Hospitals & Diagnostic Laboratories, Academic & Research Institutes), By Region, And Segment Forecasts, 2023 To 2030

Breast cancer core needle biopsy uses a hollow needle to remove a tube-shaped piece of tissue with a spring-loaded or vacuum-powered system. The tissue sample is used further for a more accurate laboratory assessment for precise determination of carcinogenicity. Growing incidence of breast cancers, recommendations for regular mammography, rising awareness, and numerous research studies are driving the market growth.

Breast cancer is the most prevalent type of cancer globally. According to WHO, there were around 2.3 million cases and 685 000 deaths globally in the year 2020 with around 7.8 million survivors. Effective and timely diagnosis is the only way to design efficient and personalized therapeutic regime with probability of survival being over 90%, given that the condition is identified early.

All breast cancer cases in low resource settings were treated by surgical removal of breast (mastectomy). The procedure has now evolved to partial removal of tissues that are cancerous in nature (lumpectomy) due to advancements in diagnostic techniques like mammography and biopsy. Researchers are working towards offering innovative solutions for early diagnosis to population in low resource setting. For instance, in April 2019, researchers at the Johns Hopkins University worked towards offering reusable, cost efficient, and sterile core biopsy device to patients. The research secured a Lemelson-MIT prize of USD 10,000.

Core needle biopsy is usually used to analyze non-palpable tumors to extract precise tissue sample. It facilitates the collection of multiple tumor tissue samples making the diagnosis process easier with an accuracy rate of around 90%. The accuracy of CNB increases with the tumor size and the number of tissue samples collected. At least four samples have to be collected to make a precise diagnosis.

Proteins are usually known as the business end of a genome. Proteins in tumors can now be analyzed with micro amounts of tissue sample obtained using a single core needle biopsy to profile proteins as well as its underlying genetic modifications. For instance, in February 2020, according to an article published by National Cancer Institute (NCI), combined molecular analyses is capable of analyzing tumors using micro amounts of tissue using micro-scaled approach. The technique was also used to gauge individual responses to therapy.

The heterogeneity in breast lesions necessitates the need for needle biopsy procedures to be guided by imaging technology such as an MRI, ultrasound, mammography, or a Computed Tomography (CT) scan. The imaging techniques are used appropriately to guide the core needle to collect tissue samples with utmost precision to avoid the possibility of misdiagnosis or over-diagnosis of the condition. For instance, in August 2022, researchers at the IMIM (Hospital del Mar Medical Research Institute), Spain, experimented a technique that involves breast biopsy guided by a contrast-mammography to be able to visualize lesions using MRI technology. The research is also published in the journal European Radiology.

Breast Cancer Core Needle Biopsy Market: Segmentation

Major companies operating in the market include Intact Medical Corporation, Ethicon Endo Surgery, Galini SRL, Leica Biosystems Nussloch GmbH, Hologic Inc., Argon Medical Devices, Encapsule Medical Devices LLC., Cook Medical Incorporated, Becton & Dickinson Company, C.R. Bard, Inc.,